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Saving myelin from microglia
The blood clotting protein fibrinogen can inadvertently promote 
multiple sclerosis (MS) when it leaks from the blood into the 
brain. According to Adams et al. (page 571), it does so by 
activating microglia and sending these cells into phagocytic 
overdrive. Interrupting this interaction may yield a treatment 
for MS that doesn’t interfere with blood clotting.
The neurological dysfunction seen in MS is caused by the 
destruction of myelin sheaths around axons. This destruction 
is thought to be driven by T helper (Th)-1 cells, and most of 
the current treatment protocols are focused on inhibiting their 
activation and entry into the CNS. But responses to anti–T cell 
therapy are variable, and inflammatory demyelination can 
sometimes occur in the absence of T cells.
One feature that all MS lesions have in common is a disruption 
in the blood–brain barrier and the leakage of fibrinogen into the 
brain through the damaged endothelia. This results in the formation 
of fibrin deposits, which are detected even before demyelination. 
These deposits also overlap with regions where resting microglia 
have differentiated into phagocytic cells that damage myelin, 
raising the possibility that clotting proteins activate microglia.
Akassoglou and colleagues had previously shown that 
fibrinogen promotes disease in mouse models of MS. The team 
now shows that fibrinogen binds to a macrophage-activating 
receptor called Mac-1 that is expressed by local microglial cells.
Mice expressing a mutant form of fibrinogen that fails to bind 
Mac-1 had fewer inflammatory lesions and less severe disease. 
Blocking the fibrinogen–Mac-1 interaction with an antagonist peptide 
prevented relapses and further myelin damage in diseased mice and 
allowed these animals to survive with improved motor function.
Fibrinogen is an attractive target for MS therapy as its 
appearance in the brain is an early sign of neurodegeneration. 
Current methods to target fibrinogen involve the use of 
anticoagulants, but their long-term use increases the risk of 
hemorrhage. The region of fibrinogen that promotes clotting is, 
however, distinct from its Mac-1–activating site. Specifically 
targeting the latter interaction might therefore be a safer option 
in MS therapy, although it is not yet clear whether T cell–
dependent pathways would also need to be blocked. 
Switching defects
Switching from one antibody isotype to 
another is a risky business that involves 
altering and cleaving DNA. B cell lym-
phomas that are stuck in the riskiest stage 
suffer repeated mutations and insertions 
that may further drive oncogenesis, ac-
cording to Lenz et al. on page 633.
Mature B cells switch from producing 
IgM to other antibody isotypes during 
their response to antigen. This process, 
known as class switch recombination 
(CSR), is initiated by an enzyme called 
activation-induced cytidine deaminase 
(AID). Modification of DNA bases by AID 
within a so-called switch region leads to 
DNA cleavage. An intervening sequence 
is looped out, and two cleaved switch 
regions are ligated together to create a new 
gene encoding a new antibody isotype.
The group had previously found 
that the activated B cell–like (ABC) 
lymphomas had high expression of AID 
compared with certain other lymphoma 
subtypes. They now find that almost 
two-thirds of the ABC lymphoma cells 
tested have abnormal CSR events and 
almost half have internal deletions in 
a switch region. The switch regions 
contained as many as 19 independent 
deletions interspersed with mutations at 
AID hot spots. The changes could be 
organized into lineage models, suggesting 
an ongoing process of aberrant processing.
AID expression is normally a tran-
sient phenomenon that occurs as B cells 
mature. ABC lymphomas, however, are 
stuck at an intermediate phase of B cell 
maturation. One consequence is sus-
tained high levels of AID expression. 
This by itself does not appear to be suffi-
cient to explain the phenotype—another 
lymphoma subtype expresses almost as 
much AID but suffers fewer problems 
with CSR. The AID overexpression in 
ABC lymphomas may be combined with 
a defect (as yet hypothetical) in proteins 
that complete CSR. The frustrated machi-
nery would turn on its own target sites, 
leading to deletions and mutations rather 
than a clean class switch.
In one lymphoma, DNA fragments 
from other chromosomes were inserted 
into the deletion sites, highlighting the 
danger inherent in aberrant class switch 
recombination. Translocations involving 
cancer-causing genes were also observed, 
suggesting that defective switching might 
sometimes further drive oncogenesis in 
these B cell lymphomas. 
Activated B cell–like (ABC) lymphomas 
have a higher rate of intraswitch deletions 
compared with other lymphomas.
Microglial activation (left) is prevented by blocking fibrin (right).